BSE: 0 | NSE: MADHAVBAUG | Hospital & Healthcare Services | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vaidya Sane Ayurved Laboratories Ltd is a below average quality company.
The key valuation ratios of Vaidya Sane Ayurved Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Vaidya Sane Ayurved Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.6% | 1.8% | 6% | 16.4% | 14.9% | - |
| Value Creation Index ⓘ | -0.6 | -0.9 | -0.6 | 0.2 | 0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||||
| Sales ⓘ | 62.5 | 75.2 | 52.3 | 74.7 | 99 | 99 |
| Sales YoY Gr. | - | 20.4% | -30.5% | 42.9% | 32.6% | - |
| Adj EPS ⓘ | 0.7 | -0.8 | 0.6 | 3.3 | 4.9 | 4.9 |
| YoY Gr. | - | -212.7% | NA | 489.3% | 49.7% | - |
| BVPS (₹) ⓘ | 0 | 0 | 14 | 34.1 | 38.8 | 38.8 |
| Adj Net Profit ⓘ | 0.5 | -0.6 | 0.4 | 3.5 | 5.2 | 5 |
| Cash Flow from Ops. ⓘ | 1.6 | 7.7 | 5.8 | -13.3 | -0.4 | - |
| Debt/CF from Ops. ⓘ | 5.5 | 0.8 | 0.2 | -0.1 | -0.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 9.6% | 32.6% | ||||
| Adj EPS ⓘ | NA | NA | NA | 49.7% | ||||
| BVPSⓘ | NA | NA | NA | 13.7% | ||||
| Share Price | - | - | - | -18.9% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5.7 | -6.6 | 4.4 | 15.2 | 13.5 | 12.7 |
| Op. Profit Mgn % ⓘ | 5 | 3.9 | 6.3 | 9.8 | 9.1 | NAN |
| Net Profit Mgn % ⓘ | 0.8 | -0.7 | 0.8 | 4.6 | 5.2 | 5.2 |
| Debt to Equity ⓘ | 1 | 0.7 | 0.1 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 46 | 56 | 37 | 44 | 0 |
| Cash Conv. Cycle ⓘ | 0 | -26 | -45 | -34 | -24 | 0 |
Return on Equity has increased versus last 3 years average to 12.70%
Sales growth has been subdued in last 3 years 9.60%
Net Profit has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 4.9 | 4.6 |
| TTM Sales (₹ Cr.) | 99 | 99.2 |
| BVPS (₹.) ⓘ | 38.8 | 38.5 |
| Reserves (₹ Cr.) ⓘ | 30 | 30 |
| P/BV ⓘ | 5.02 | 5.07 |
| PE ⓘ | 39.50 | 42.42 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 205 |
| Equity (₹ Cr.) | 10.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 84.1 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|
| Sales | 62 | 75 | 52 | 75 | 99 |
| Operating Expenses ⓘ | 59 | 72 | 49 | 67 | 90 |
| Manufacturing Costs | 2 | 3 | 3 | 3 | 3 |
| Material Costs | 17 | 21 | 17 | 22 | 28 |
| Employee Cost | 15 | 21 | 13 | 18 | 21 |
| Other Costs ⓘ | 25 | 27 | 16 | 24 | 38 |
| Operating Profit ⓘ | 3 | 3 | 3 | 7 | 9 |
| Operating Profit Margin (%) | 5.0% | 3.9% | 6.3% | 9.8% | 9.1% |
| Other Income ⓘ | 0 | 0 | 0 | 0 | 1 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 2 | 2 | 2 | 2 | 3 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 0 | 0 | 5 | 7 |
| Tax ⓘ | 0 | 0 | 0 | 1 | 2 |
| Profit After Tax | 0 | -1 | 0 | 3 | 5 |
| PAT Margin (%) | 0.8% | -0.7% | 0.7% | 4.6% | 5.2% |
| Adjusted EPS (₹) | 0.7 | -0.8 | 0.6 | 3.3 | 4.9 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 5% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 9 | 8 | 10 | 36 | 41 | |||||
| Share Capital ⓘ | 0 | 0 | 0 | 11 | 11 | |||||
| Reserves ⓘ | 9 | 8 | 10 | 25 | 30 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |||||
| Debt | 9 | 6 | 1 | 1 | 0 | |||||
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | |||||
| Short Term Debt | 9 | 6 | 1 | 1 | 0 | |||||
| Trade Payables | 6 | 8 | 7 | 7 | 9 | |||||
| Others Liabilities ⓘ | 5 | 7 | 8 | 6 | 5 | |||||
| Total Liabilities ⓘ | 29 | 29 | 26 | 50 | 55 | |||||
Fixed Assets | ||||||||||
| Gross Block | 21 | 23 | 27 | 29 | 35 | |||||
| Accumulated Depreciation | 5 | 7 | 10 | 12 | 14 | |||||
| Net Fixed Assetsⓘ | 16 | 16 | 17 | 17 | 21 | |||||
| CWIP ⓘ | 2 | 4 | 0 | 1 | 2 | |||||
| Investmentsⓘ | 0 | 0 | 0 | 21 | 15 | |||||
| Inventories | 4 | 3 | 2 | 2 | 3 | |||||
| Trade Receivables | 4 | 2 | 3 | 4 | 6 | |||||
| Cash Equivalents | 1 | 1 | 1 | 3 | 2 | |||||
| Others Assetsⓘ | 3 | 3 | 3 | 3 | 6 | |||||
| Total Assets ⓘ | 29 | 29 | 26 | 50 | 55 | |||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 2 | 8 | 6 | -13 | 0 |
| PBT ⓘ | 1 | 0 | 2 | 5 | 7 |
| Adjustment ⓘ | 2 | 3 | 2 | 2 | 1 |
| Changes in Working Capital ⓘ | -1 | 5 | 3 | -19 | -6 |
| Tax Paid ⓘ | 0 | 0 | -1 | -1 | -3 |
| Cash Flow From Investing Activity ⓘ | -10 | -4 | -1 | -8 | 1 |
| Capex | -9 | -4 | -1 | -8 | 1 |
| Net Investments | 0 | 0 | 0 | 0 | -1 |
| Others ⓘ | -1 | 0 | 0 | 0 | 1 |
| Cash Flow From Financing Activityⓘ | 8 | -4 | -5 | 22 | -1 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 23 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | -1 |
| Interest Paid ⓘ | -1 | -1 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 8 | -3 | -5 | 0 | 0 |
| Net Cash Flow ⓘ | -1 | 0 | 0 | 2 | -1 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 5.65 | -6.56 | 4.36 | 15.2 | 13.53 | |||||
| ROCE (%) | 9.04 | 4.73 | 7.69 | 22.53 | 19.94 | |||||
| Asset Turnover Ratio | 2.16 | 2.59 | 1.91 | 1.97 | 1.88 | |||||
| PAT to CFO Conversion(x) | N/A | N/A | N/A | -4.33 | 0 | Working Capital Days | ||||
| Receivable Days | 21 | 15 | 18 | 15 | 18 | |||||
| Inventory Days | 21 | 16 | 16 | 8 | 9 | |||||
| Payable Days | 138 | 124 | 162 | 117 | 108 | |||||
Vaidya Sane Ayurved Laboratories (Madhavbaug) is a unique medical service institution that strives to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda. The company’s approach to treatment using non-invasive, multidisciplinary and innovative therapies which has helped establish it as a dependable option for treating the chronic ailments. It is a health care provider primarily in the India’s chronic care ecosystem. It provides its healthcare services through Madhavbaug clinics. As on November 30, 2021, the company operates 274 clinics across Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Goa, Karnataka, Delhi and Chhattisgarh. Out of these 52 are company owned and 222 are franchise clinics. It also operates two cardiac prevention and rehabilitation hospitals in Khopoli and Nagpur respectively. Currently, the company’s network includes 274 Clinics and 2 Fully equipped Hospital.
At the company’s clinics and hospitals, it use modern diagnostics, diet and physiotherapy and advanced Ayurveda to provide Heart disease, Diabetes, Hypertension & Obesity reversal treatments to its patients. This helps in improving the exercise tolerance of patients - improvement in grade of symptoms, improvement in maximum oxygen uptake, reduction in Hba1c, and metabolic equivalents (METs).
Business area of the company
The company is a medical service institution engaged in the treatment of chronic ailments like cardiac disease, diabetes, hypertension, and obesity by combining modern technology with the traditional Ayurveda practices.
Major Events and Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
